AR087070A1 - Proteinas de fusion liberadoras de relaxina y usos de las mismas - Google Patents
Proteinas de fusion liberadoras de relaxina y usos de las mismasInfo
- Publication number
- AR087070A1 AR087070A1 ARP120102439A ARP120102439A AR087070A1 AR 087070 A1 AR087070 A1 AR 087070A1 AR P120102439 A ARP120102439 A AR P120102439A AR P120102439 A ARP120102439 A AR P120102439A AR 087070 A1 AR087070 A1 AR 087070A1
- Authority
- AR
- Argentina
- Prior art keywords
- relaxin
- fusion
- hem
- pcs
- life
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente solicitud proporciona proteínas de fusión de Relaxina, en las que un ligador conecta el extremo carboxi-terminal de Relaxina con un resto proteínico que prolonga la semivida y el ligador comprende un sitio de escisión de proteasa. En consecuencia, la solicitud proporciona polipéptidos de fusión de Relaxina con semivida prolongada por lo cual la proteína de fusión por sí misma sirve como depósito para la liberación de la Relaxina biológicamente activa. Además, la solicitud proporciona secuencias de ácidos nucleicos que codifican los anteriores polipéptidos de fusión, vectores que contienen los mismos, células que expresan los polipéptidos de fusión de Relaxina, composiciones farmacéuticas y uso médico de tales polipéptidos de fusión. Reivindicación 1: Una proteína de fusión que comprende Relaxina-PCS-HEM o HEM-PCS-Relaxina, en la que la Relaxina comprende un polipéptido de la cadena A de Relaxina o una variante funcional de la misma, y un polipéptido de la cadena B de Relaxina o una variante funcional de la misma, PCS comprende un sitio de escisión de endo-proteasa, y HEM es un resto proteínico que prolonga la semivida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11173328 | 2011-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR087070A1 true AR087070A1 (es) | 2014-02-12 |
Family
ID=46506356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120102439A Pending AR087070A1 (es) | 2011-07-08 | 2012-07-05 | Proteinas de fusion liberadoras de relaxina y usos de las mismas |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140148390A1 (es) |
EP (1) | EP2729494A1 (es) |
JP (1) | JP2014529293A (es) |
KR (1) | KR20140039257A (es) |
CN (1) | CN103649116A (es) |
AR (1) | AR087070A1 (es) |
AU (1) | AU2012283235A1 (es) |
BR (1) | BR112014000474A2 (es) |
CA (1) | CA2840944A1 (es) |
IL (1) | IL229753A0 (es) |
MX (1) | MX2014000316A (es) |
RU (1) | RU2014104302A (es) |
TW (1) | TW201317259A (es) |
WO (1) | WO2013007563A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140054009A (ko) | 2011-07-01 | 2014-05-08 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 릴랙신 융합 폴리펩타이드 및 그의 용도 |
AR094147A1 (es) * | 2012-12-27 | 2015-07-15 | Bayer Pharma Aktiengellschaft | Polipeptidos de fusion con actividad de relaxina y sus usos |
UY35671A (es) * | 2013-07-25 | 2015-02-27 | Novartis Ag | Bioconjugados de polipéptidos de apelina sintética |
CN105612174A (zh) * | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的二硫化物环状多肽 |
SG11201600211XA (en) * | 2013-07-25 | 2016-02-26 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
CN105612173A (zh) * | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的环状apelin衍生物 |
ES2927607T3 (es) | 2013-09-13 | 2022-11-08 | Scripps Research Inst | Agentes terapéuticos modificados y composiciones de los mismos |
EP4212180A1 (en) | 2013-12-18 | 2023-07-19 | The Scripps Research Institute | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
US10081662B2 (en) | 2014-04-17 | 2018-09-25 | The Florey Institute Of Neuroscience And Mental Health | Modified relaxin B chain peptides |
US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
MA41794A (fr) * | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
WO2017100540A2 (en) | 2015-12-09 | 2017-06-15 | The California Institute For Biomedical Research | Relaxin immunoglobulin fusion proteins and methods of use |
EP3455241B1 (en) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Method of cleaning and/or sanitizing a separation matrix |
US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
MA45051A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant la relaxine |
SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
EP3553079A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
EP3553081A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
CA3119402A1 (en) * | 2018-11-20 | 2020-05-28 | Universitat Heidelberg | Relaxin receptor 1 for use in treatment and prevention of heart failure |
TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
KR20240121820A (ko) * | 2021-12-15 | 2024-08-09 | 메디뮨 리미티드 | 이형이량체 릴랙신 융합체를 이용한 치료 |
TW202409074A (zh) * | 2022-05-07 | 2024-03-01 | 大陸商北京拓界生物醫藥科技有限公司 | 鬆弛素或類似物的融合蛋白及其醫藥用途 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
HUP9902056A3 (en) | 1996-01-17 | 2002-02-28 | Novo Nordisk As | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
WO1999003861A1 (en) | 1997-07-16 | 1999-01-28 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
EP1278544A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
US7094875B2 (en) * | 2000-06-23 | 2006-08-22 | Maxygen, Inc. | Co-stimulatory polypeptides |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
UA81897C2 (uk) | 2000-12-07 | 2008-02-25 | Эли Лилли Энд Компани | Гетерологічний пептидильований глюкагон-1-подібний білок та його застосування для для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння та/або інсулінонезалежний діабет |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
EP1448599A2 (en) * | 2001-11-14 | 2004-08-25 | Lorantis Limited | Inhibitors of the notch signalling pathway for use in the treatment of cancer |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
RU2512933C2 (ru) * | 2008-05-16 | 2014-04-10 | Кортера, Инк. | Способ лечения хронической сердечной недостаточности |
CA2731546C (en) * | 2008-07-23 | 2013-11-19 | Hanmi Holdings Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
WO2010054699A1 (en) | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
US8389475B2 (en) | 2009-08-10 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Relaxin analogs |
-
2012
- 2012-07-04 CN CN201280033914.7A patent/CN103649116A/zh active Pending
- 2012-07-04 BR BR112014000474A patent/BR112014000474A2/pt not_active IP Right Cessation
- 2012-07-04 JP JP2014517780A patent/JP2014529293A/ja active Pending
- 2012-07-04 KR KR1020147000123A patent/KR20140039257A/ko not_active Application Discontinuation
- 2012-07-04 MX MX2014000316A patent/MX2014000316A/es not_active Application Discontinuation
- 2012-07-04 WO PCT/EP2012/062956 patent/WO2013007563A1/en active Application Filing
- 2012-07-04 RU RU2014104302/10A patent/RU2014104302A/ru not_active Application Discontinuation
- 2012-07-04 EP EP12733672.5A patent/EP2729494A1/en not_active Withdrawn
- 2012-07-04 CA CA2840944A patent/CA2840944A1/en not_active Abandoned
- 2012-07-04 AU AU2012283235A patent/AU2012283235A1/en not_active Abandoned
- 2012-07-04 US US14/131,643 patent/US20140148390A1/en not_active Abandoned
- 2012-07-05 AR ARP120102439A patent/AR087070A1/es active Pending
- 2012-07-06 TW TW101124347A patent/TW201317259A/zh unknown
-
2013
- 2013-12-02 IL IL229753A patent/IL229753A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL229753A0 (en) | 2014-01-30 |
TW201317259A (zh) | 2013-05-01 |
WO2013007563A1 (en) | 2013-01-17 |
JP2014529293A (ja) | 2014-11-06 |
BR112014000474A2 (pt) | 2017-02-21 |
AU2012283235A1 (en) | 2014-01-09 |
EP2729494A1 (en) | 2014-05-14 |
CA2840944A1 (en) | 2013-01-17 |
MX2014000316A (es) | 2014-02-19 |
CN103649116A (zh) | 2014-03-19 |
US20140148390A1 (en) | 2014-05-29 |
KR20140039257A (ko) | 2014-04-01 |
RU2014104302A (ru) | 2015-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR087070A1 (es) | Proteinas de fusion liberadoras de relaxina y usos de las mismas | |
RS53559B1 (en) | INSULIN FORMULATIONS WITH LONG TERM ACTION | |
AR087020A1 (es) | Polipeptidos de fusion de relaxina y usos de los mismos | |
CL2018003148A1 (es) | Proteínas de fusión y usos de las mismas. | |
AR109513A2 (es) | Un complejo proteico, un método para preparar un complejo proteico y una composición farmaceutica que lo comprende | |
PE20160244A1 (es) | Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos | |
PE20151205A1 (es) | Formulaciones que contienen linaclotida para administracion oral | |
ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
UY35703A (es) | Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos | |
DOP2012000244A (es) | Nuevos péptidos y métodos para su preparación y uso | |
GT200900229A (es) | Coagonistas de receptor de glucagón/glp-1 | |
AR077764A1 (es) | Polipeptidos selectivos para integrina alfavbeta 3 conjugados a una variante de seroalbumina humana (hsa) y usos farmaceuticos de los mismos | |
CR10756A (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
ATE509634T1 (de) | Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel | |
PE20140160A1 (es) | Polipeptidos de relaxina modificados y sus usos | |
CL2013003598A1 (es) | Compuestos derivados de benzooxazepinona, moduladores de canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades seleccionadas de arritmias, insuficiencia cardiaca, angina, infarto al miocardio, diabetes, entre otras | |
PE20150650A1 (es) | Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida | |
AR067980A1 (es) | Peptidos de cdh3 y agentes que los comprenden | |
AR083126A1 (es) | Composicion vacunal para el control de las infestaciones por ectoparasitos | |
CO7131365A2 (es) | Factores de coagulación de acción prolongada y métodos de producción de los mismos | |
AR064254A1 (es) | Maiz extraido con solvente | |
AR092840A1 (es) | Elaboracion de degarelix | |
AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato | |
AR111341A1 (es) | Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo | |
AR090244A1 (es) | Formulacion de anticuerpo anti-selectina p |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |